Molecule kills elderly cells, reduces signs of aging in mice – Science Magazine

The mouse in the back received a drug to eliminate senescent cells and looks healthier than its scraggly companion.

Peter de Keizer

By Mitch LeslieMar. 23, 2017 , 12:00 PM

Even if you arent elderly, your body is home to agents of senilityfrail and damaged cells that age us and promote disease. Now, researchers have developed a molecule that selectively destroys these so-called senescent cells. The compound makes old mice act and appear more youthful, providing hope that it may do the same for us.

Its definitely a landmark advance in the field, says cell and molecular biologist Francis Rodier of the University of Montreal in Canada who wasnt connected to the study. This is the first time that somebody has shown that you can get rid of senescent cells without having any obvious side effects.

As we get older, senescent cells build up in our tissues, where researchers think they contribute to illnesses such as heart disease, arthritis, and diabetes. In the past, scientists have genetically modified mice to dispatch their senescent cells, allowing the rodents to live longer and reducing plaque buildup in their arteries. Such genetic alterations arent practical for people, but researchers have reported at least seven compounds, known as senolytics, that kill senescent cells. A clinical trial is testing two of the drugs in patients with kidney disease, and other trials are in the works.

However, current senolytic compounds, many of which are cancer drugs, come with downsides. They can kill healthy cells or trigger side effects such as a drop in the number of platelets, the cellular chunks that help our blood clot.

Cell biologist Peter de Keizer of Erasmus University Medical Center in Rotterdam, the Netherlands, and colleagues were investigating how senescent cells stay alive when they uncovered a different strategy for attacking them. Senescent cells carry the type of DNA damage that should spur a protective protein, called p53, to put them down. Instead, the researchers found that a different protein, FOXO4, latches onto p53 and prevents it from doing its duty.

To counteract this effect, De Keizer and colleagues designed a molecule, known as a peptide, that carries a shortened version of the segment of FOXO4 that attaches to p53. In a petri dish, this peptide prevented FOXO4 and p53 from hooking up, prompting senescent cells to commit suicide. But it spared healthy cells.

The researchers then injected the molecule into mutant mice that age rapidly. These rodents live about half as long as normal mice, and when they are only a few months old, their fur starts to fall out, their kidneys begin to falter, and they become sluggish. However, the peptide boosted the density of their fur, reversed the kidney damage, and increased the amount of time they could scurry in a running wheel, the scientists report online today in Cell. When the researchers tested the molecule in normal, elderly mice, they saw a similar picture: In addition to helping their kidneys and fur, the molecule also increased their willingness to explore their surroundings.

The paper adds a potentially new way to target senescent cells, says diabetes researcher James Kirkland of the Mayo Clinic in Rochester, Minnesota. He cautions, however, that peptides like the one De Keizer and colleagues developed have their own limitations. The digestive system destroys them, so they can only be delivered through inhalation or an injectionyou cant just swallow a pill, he notes.

Although the molecule did not reduce the number of platelets in either mouse group, killing off large numbers of senescent cells could still trigger a potentially fatal complication sometimes suffered by cancer patients. Moreover, senescent cells foster wound healing, and destroying the cells could impair this ability.

Thats why De Keizer says he and his colleagues plan to move cautiously with their molecule. I dont think you should start treating frail people in their 90s. Instead, he says, they want to determine whether the molecule kills cancer cells, which share some similarities with senescent cells, starting with the brain tumor glioblastoma. If the compound continues to prove safe, they can think about testing the peptide against age-related diseases or even aging itself.

Please note that, in an effort to combat spam, comments with hyperlinks will not be published.

Read the original:
Molecule kills elderly cells, reduces signs of aging in mice - Science Magazine

Stem Cell Therapy Restores Sexual Function In Impotent Men – News18

Stem cell therapy can restore sufficient erectile function to allow previously impotent men to have spontaneous intercourse, show results of an early clinical trial.

"What we have done establishes that this technique can lead to men recovering a spontaneous erection -- in other words, without the use of other medicines, injections, or implants," said lead researcher Martha Haahr from Odense University Hospital in Denmark.

Results presented at the European Association of Urology conference in London showed that eight out of 21 participants in the study successfully regained sexual function.

"We are now beginning a larger Phase-2 trial to better evaluate its effectiveness and confirm its safety," Haahr said.

In recent years several groups have worked to develop stem cell therapy as a cure for erectile dysfunction, but until now the improvements have not been sufficient to allow affected men to achieve full sexual intercourse.

Erectile dysfunction to some degree affects nearly half of men between the ages of 40 and 70.

There are several possible causes, including surgery (for example, prostate surgery), high blood pressure, diabetes, cardiovascular disease and psychological problems.

Current remedies -- which include medications such as PDE5 inhibitors (such as Viagra and Cialis), injections, or penile implants -- have some disadvantages, so scientists have been searching to find a way which restores natural sexual function.

The present work focuses on patients with physical damage, caused by surgery (radical prostatectomy) for prostate cancer.

The research group, from Odense in Denmark, used stem cells taken from abdominal fat cells via liposuction (under a general anaesthetic).

None of the 21 men reported significant side effects over the trial period, or in the following year, according to the study.

After isolating the stem cells, they were injected into the corpus cavernosum area of the penis. The patients were able to be discharged the same day.

Within six months of the treatment, eight of the 21 patients reported that they had recovered sufficient erectile function to achieve penetrative sexual activity.

This improvement has been maintained for a year, indicating that this treatment may confer long-term benefits.

"We are the first to use a man's own fat stem cells as a treatment for erectile dysfunction in a clinical trial. The technique has been trialed in animal work, but this is the first time stem cell therapy has allowed patients to recover sufficient erectile function to enable intercourse," Haahr said.

Read more from the original source:
Stem Cell Therapy Restores Sexual Function In Impotent Men - News18

BioStem Technologies, Inc. Announces Completion of 503b … – Yahoo Finance

OAKLAND PARK, FL--(Marketwired - Mar 24, 2017) - BioStem Technologies, Inc. ( OTC PINK : BSEM ) ("BSEM" or "the company"), an emerging International BioTech company, celebrated the opening of its new laboratory and corporate offices with a ribbon cutting ceremony hosted by the BioStem Technologies executive team. BSEM's Founder and CEO, Henry Van Vurst, commented, "With the recent regulation changes we amended our original facility design to comply with FDA 503b regulations, which caused an extension to our timeline, but I couldn't be prouder of this new state-of-the-art facility. Cutting the ribbon with Mayor Lamar Fisher (City of Pompano Beach) was a very proud moment for the entire BSEM team, and it is a testament to how far we have come since the Company's inception in 2014."

The facility is a showcase of quality that will enable BSEM to leverage its vertical integration strategy in the Health, Wellness and Biotechnology sectors. The lab will serve as the Quality, R&D, and Pharmaceutical Manufacturing Laboratory, not only for the Company's in-house operations, but also for its contract formulation and contract manufacturing services. The Company is in the process of finalizing its certifications for the ISO 8, 7, and 5 suites, as well as validation of the cGMP and cGLP areas. Corporate operations are expected to move to the new facility in Q2 2017, while the operations of Qualified Pharma Ingredients, one of the company's subsidiaries, will remain at its current location in Oakland Park, Florida.

About BioStem Technologies, Inc. ( OTC PINK : BSEM ): BioStem Technologies, Inc. ( OTC PINK : BSEM ) is in the business of regenerative medicine and antiaging strategies throughout the United States, Europe, and Mexico. The Company's mission is to conquer the effects of biological aging (and related acute disease), and its strategy is to discover, develop, produce, and deliver the most effective stem cell and wellness products in the world. The Company is comprised of a diverse group of scientists, physicians, and industry visionaries who are creating innovative products for helping customers live their best, feel their best, and be their best. The company operates six strategic business units -- BioStem Cell Therapy, BioStem Wellness, BioStem Pharmaceuticals, Qualified Pharma Ingredients, BioBlue, and BioStem International -- providing a diversified line of products and services that include: clinical stem cell therapy, stem cell R&D, state-of-the-art laboratory services, pharmaceuticals, nutraceuticals, cosmeceuticals, API repackaging, and medical tourism.

Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.

Read the original:
BioStem Technologies, Inc. Announces Completion of 503b ... - Yahoo Finance

Stem Cell Center epitomizes PPP – Kuwait Times

Opens mid-September; first of its kind in the Gulf

KUWAIT: An artists rendition of the Sheikha Salwa Sabah Al-Ahmad Center for Stem Cell and Umbilical Cord. (inset) Masharee Al-Khair board member and treasurer Abdul-Aziz Al-Jassar and KIPCO Deputy Chairman Faisal Al-Ayyar KUNA

KUWAIT: The private sector in Kuwait has come to play a major role in various fields of the economic scene, for the good of the entire society, within the concept of social responsibility of the business. This role has been in many cases fulfilled in partnership with the public sector. The Sheikha Salwa Sabah Al-Ahmad Center for Stem Cell and Umbilical Cord, which is currently under construction, offers a good model of the public-private partnership (PPP).

Once completed, the center would help scientists are in their research to explore how the cells can be used for a better quality of life for patients suffering from genetic diseases, for instance. Such efforts have already been fruitful, as discoveries in the field have raised hope for people with incurable diseases such as blood cancers, disorders of the immunity system and metabolism, to have a better standard of life through stem cell transplant.

12,000 square meters The center is being built on a total area of 12,000 square meters in Al-Sabah Health Zone, opposite to the Maternity Hospital. It includes a three-floor main building and one for utilities, in addition to external landscaping and parking. The facility also includes testing and research laboratories, blood and cord storage banks, research and medical libraries, as well as a lecture theater.

On behalf of the Kuwait Projects Company (KIPCO) and the Group companies, the Masharee Al-Khair (projects for good) Charity Organization provided a KD 7 million ($23 million) donation for the Gulf regions first-ever center to be dedicated to stem cell research and the storage of umbilical cords.

In addition, the Advanced Technology Company (ATC), a member of the KIPCO Group, has pledged to provide state-of-the-art equipment for the centers specialized laboratories, cooling systems and stem cell storage facilities. ATCs contribution is valued at KD 1 million.

Once completed in mid-September 2017, the Sheikha Salwa Sabah Al-Ahmad Center for Stem Cell and Umbilical Cord will be handed over to the Ministry of Health. KIPCOs donation for the center has been prompted by its strong belief in the major role of the private sector in all vital sectors in Kuwait so as to cope with the accelerating scientific progress worldwide. It also offers a model example of PPP, for promoting medical services in the country.

Landmark achievement The center is the first of its kind in the Gulf region, and a landmark achievement in the health sector, said Faisal Al-Ayyar, KIPCO Deputy Chairman. He noted that KIPCO Group of companies allocate one percent of their annual profits for Masharee Al-Khair to offer support to social, health and educational scenes. Ayyar expressed hope that the day would come when storing stem cells would be as easy as ever, and treatment through them a first choice for incurable diseases, boasting KIPCOs philanthropic role.

Abdul-Aziz Al-Jassar, Masharee Al-Khairs board member and treasurer, said meanwhile that KIPCOs donation for the center was prompted by a strong belief in the vital role of the private sector supporting the governments development plans. We pin great hopes on the would-be center, that will no doubt play a major role for promoting medical research, Jassar said. Founded in 1975, KIPCO has since become one of the Middle East and North African (MENA) regions most successful companies. With holdings in sectors such as financial services, media, manufacturing and real estate, KIPCO Group comprises over 60 companies and employs over 12,000 people in 24 countries. KUNA

Go here to read the rest:
Stem Cell Center epitomizes PPP - Kuwait Times

Scientists know how to grow human heart tissue – Institute …

Scientists used stem cells to grow human heart tissue that contracted spontaneously in a petri dish marking progress in the quest to manufacture transplant organs.

A team from the University of Pittsburgh, Pennsylvania, used induced pluripotent stem (iPS) cells generated from human skin cells to create precursor heart cells called MCPs. iPS cells are mature human cells reprogrammed into a versatile, primitive state from which they can be prompted to develop into any kind of cell of the body. The primitive heart cells created in this way were attached to a mouse heart scaffold from which the researchers had removed all mouse heart cells, they wrote in the journal Nature Communications.

The scaffold is a network of non-living tissue composed of proteins and carbohydrates to which cells adhere and grow on. Placed on the 3D scaffold, the precursor cells grew and developed into heart muscle, and after 20 days of blood supply the reconstructed mouse organ began contracting again at the rate of 40 to 50 beats per minute, said a University of Pittsburgh statement.

It is still far from making a whole human heart, added senior researcher Lei Yang. Ways have to be found to make the heart contract strongly enough to pump blood effectively and to rebuild the hearts electrical conduction system. However, we provide a novel resource of cells iPS cell-derived MCPs for future heart tissue engineering, Yang told AFP by email. We hope our study would be used in the future to replace a piece of tissue damaged by a heart attack, or perhaps an entire organ, in patients with heart disease.

According to the World Health Organisation, an estimated 17 million people die of cardiovascular ailments every year, most of them from heart disease. Due to a shortage of donor organs, end-stage heart failure is irreversible, said the study. More than half of patients with heart disease do not benefit from drugs. Heart tissue engineering holds a great promise based on the reconstruction of patient-specific cardiac muscle, the researchers wrote.

Last month, scientists in Japan said they had grown functional human liver tissue from stem cells in a similar process. Creating lab-grown tissue to replenish organs damaged by accident or disease is a Holy Grail for the pioneering field of stem cell research. Until a few years ago, when iPS cells were created, the only way to obtain stem cells was to harvest them from human embryos. This was controversial because it required the destruction of the embryo, a process to which religious conservatives and others object.

Source: http://news.sudanvisiondaily.com

As the Chief Doctor of the Institute of Cell Therapy, Y.V.Gladkikh, MD, PhD, Dr. med. sc. commented: In addition to laboratory success in obtaining the functional cardiac tissue, currently there is evidence of successful implantations of heart valves and blood vessels fragments, grown from stem cells, to patients. And in 2012, the Ministry of Health of Ukraine officially approved method of treatment of critical limbs ischemia with the use of cell preparation Angiostem, developed by the biotechnological laboratory of the Institute of Cell Therapy.

Follow this link:
Scientists know how to grow human heart tissue - Institute ...

New tools to study the origin of embryonic stem cells – Phys.Org

March 23, 2017 Immunofluorescence microscopy reveals the different protein profiles of immature stem cells (coloured pink) and mature stem cells (coloured green). Credit: Sarita Panula

Researchers at Karolinska Institutet have identified cell surface markers specific for the very earliest stem cells in the human embryo. These cells are thought to possess great potential for replacing damaged tissue but until now have been difficult to distinguish from classical embryonic stem cells. The study is published in the prestigious journal Cell Stem Cell.

During the first week of fertilisation, the embryo grows from a single cell into a blastocyst, a hollow cluster of a few hundred cells. The blastocyst then attaches itself to the wall of the uterus (implantation), and for a limited period from fertilisation to a few days after implantation the embryo contains pluripotent stem cells. These cells can develop into all the body's cell types and are therefore of considerable interest to the field of regenerative and reparative medicine.

A few years ago, it was discovered that there are two stages for human pluripotent stem cells, corresponding to the pre-implanted and post-implanted embryonic cells. Although the classical stem cells used in regenerative medicine are isolated from the pre-implanted embryo, they have adopted a mature stage that is most likely more similar to a post-implantation embryo. A new type of pluripotent cell that genuinely corresponds to the more immature, pre-implantation stage has been identified and can now be cultivated in the laboratory. These immature stem cells are of great scientific interest since they are believed to have the potential to build certain cell types that are difficult to obtain from the classical stem cells, and they may also be easier to cultivate and manipulate in the laboratory.

Fredrik Lanner's research team at Karolinska Institutet and their colleagues in Peter Rugg-Gunn's team at Cambridge's Babraham Institute in the UK have now developed a tool for separating the two stem cell states. They have screened combinations of antibodies that bind to specific proteins on the surface of the immature and mature stem cells and that can be used for flow cytometry, a common laboratory technique for sorting cells.

"We've not had cell surface markers for the different stem cell states before, which has made it hard to study them," says Fredrik Lanner, Assistant Professor at Karolinska Institutet's Department of Clinical Science, Intervention and Technology. "We now have a simple tool for identifying and sorting the cells, which benefits future stem cell research and basic research on early embryonic development."

Mature embryonic stem cells cultivated in the laboratory can, under the right conditions, be backed up in their development to the more immature stem cell type. The researchers tested their technique on such cultivated stem cells of both a mature and immature type, and on donated human embryos left over from IVF treatments. As expected, only the immature stem cell type was identified in such pre-implanted embryos, which indicates that the antibodies are highly specific.

"It is at the point of implantation that the stem cells go through this change and 'mature', which is also a highly critical time for the embryo," says Dr Lanner. "These cells are therefore also of interest to infertility research."

Explore further: Vitamins and aminoacids regulate stem cell biology

More information: 'Comprehensive Cell Surface Protein Profiling Identifies Specific Markers of Human Naive and Primed Pluripotent States', Amanda J. Collier, Sarita P. Panula, John Paul Schell, Peter Chovanec, Alvaro Plaza Reyes, Sophie Petropoulos, Anne E. Corcoran, Rachael Walker, Iyadh Douagi, Fredrik Lanner, Peter J. Rugg-Gunn. Cell Stem Cell, online 23 March 2017, DOI: 10.1016/j.stem.2017.02.014

An International Reserach Team coordinated by Igb-Cnr has discovered a key role of vitamins and amino acids in pluripotent stem cells. The research is published in Stem Cell Reports, and may provide new insights in cancer ...

Researchers at Karolinska Institutet and the Ludwig Cancer Research in Stockholm, Sweden have conducted a detailed molecular analysis of the embryo's first week of development. Their results show that there are considerable ...

A new method allows for large-scale generation of human embryonic stem cells of high clinical quality. It also allows for production of such cells without destroying any human embryos. The discovery is a big step forward ...

Researchers at the Babraham Institute have revealed a new understanding of the molecular switches that control gene activity in human embryonic stem cells. This insight provides new avenues for improving the efficiency of ...

Freiburg plant biologist Prof. Dr. Thomas Laux and his research group have published an article in the journal Developmental Cell presenting initial findings on how shoot stem cells in plants form during embryogenesis, the ...

Not too shabby, humans. New research shows that certain primate stem cells have pluripotency superior to some types derived from mice. The study, published in Nature, maps how pluripotency differs among mice, monkeys, and ...

When the mighty orca breaks to the surface and exhales, the whale sprays an array of bacteria and fungi in its his breath, scientists said, some good, and some bad such as salmonella.

Researchers at Lancaster University have found a way to detect subtle early warning signs that reveal a frog population is at risk from pollution.

Australian National University biologists have found the first evidence of mass extinction of Australian animals caused by a dramatic drop in global temperatures 35 million years ago.

A group of scientists in Israel and Germany, led by Prof. Sebastian Kadener from the Hebrew University of Jerusalem, have discovered a protein-encoding function for circular RNA. This kind of RNA molecule is highly active ...

A team spanning Baylor College of Medicine, Rice University, Texas Children's Hospital and the Broad Institute of MIT and Harvard has developed a new way to sequence genomes, which can assemble the genome of an organism, ...

(Phys.org)A team of researchers affiliated with several institutions in Hong Kong and mainland China has isolated a change in a single nucleotide that is responsible for allowing the H7N9 flu virus to replicate in both ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Here is the original post:
New tools to study the origin of embryonic stem cells - Phys.Org

The stem cell procedure that may change the sports medicine field in 2017 5 observations – Becker’s Orthopedic & Spine

Physicians, healthcare professionals and members of the MLB community will keep a close eye on Red Sox pitcher Andrew Pomeranz's recovery from a potentially career-saving stem cell procedure, according to The Boston Globe.

Here are five things to know:

1. Steve Yoon, MD, of the Los Angeles-based Kerlan-Jobe Orthopaedic Clinic extracted bone marrow from Mr. Pomeranz's hip bone and back and injected it into his flexor tendon.

2. Mr. Pomeranz was motivated to undergo the procedure after fellow pitchers Garrett Richards and Andrew Heaney opted for the treatment instead of undergoing Tommy John Surgery to treat the partial tears in their ulnar collateral ligaments.

3. Lyle Cain, MD, of Birmingham, Ala.-based Andrews Sports Medicine & Orthopedic Center said, "Stem cells are a way to try to deliver the chemicals to cells and the chemical attractive factors to that area to allow the body to heal that tissue. That's what PRP was used for as well. Stem cells have more promise because not only do they have the chemicals that platelet-rich plasma has, but you're also putting some of the healing cells themselves in that area."

4. Pitcher Bartolo Colon was the first baseball player known to receive stem cell treatment when he received injections in his injured rotator cuff and elbow in the Dominican Republic in 2010. The 43-year-old pitcher's career was resurrected following the operation, partially prompting the method's increased popularity.

5. If Mr. Pomeranz has a successful 2017 season, the number of players undergoing stem cell procedures may rise.

More articles on sports medicine:

Nearly-paralyzed ex-NFL player promoting neck injury research 4 takeaways

Does single-sport focus increase athlete injuries? 5 things to know

Knee application segment leads global sports medicine market 8 observations

Go here to see the original:
The stem cell procedure that may change the sports medicine field in 2017 5 observations - Becker's Orthopedic & Spine

Peptide targeting senescent cells restores stamina, fur, and kidney function in old mice – Medical Xpress

March 23, 2017 Two fast-aging mice. The mouse on the left was treated with a FOXO4 peptide, which targets senescent cells and leads to hair regrowth in ten days. The mouse on the right was not treated with the peptide. Credit: Peter L.J. de Keizer

Regular infusions of a peptide that can selectively seek out and destroy broken-down cells that hamper proper tissue renewal, called senescent cells, showed evidence of improving healthspan in naturally-aged mice and mice genetically engineered to rapidly age. The proof-of-concept study, published March 23 in Cell, found that an anti-senescent cell therapy could reverse age-related loss of fur, poor kidney function, and frailty. It is currently being tested whether the approach also extends lifespan, and human safety studies are being planned.

The peptide took over four years of trial and error to develop and builds on nearly a decade of research investigating vulnerabilities in senescent cells as a therapeutic option to combat some aspects of aging (Trends in Molecular Medicine, 10.1016/j.molmed.2016.11.006). It works by blocking the ability of a protein implicated in senescence, FOXO4, to tell another protein, p53, not to cause the cell to self-destruct. By interfering with the FOXO4-p53 crosstalk, the peptide causes senescent cells to go through apoptosis, or cell suicide.

"Only in senescent cells does this peptide cause cell death," says senior author Peter de Keizer, a researcher of aging at Erasmus University Medical Center in the Netherlands. "We treated mice for over 10 months, giving them infusions of the peptide three times a week, and we didn't see any obvious side effects. FOXO4 is barely expressed in non-senescent cells, so that makes the peptide interesting as the FOXO4-p53 interaction is especially relevant to senescent cells, but not normal cells."

Results appeared at different times over the course of treatment. Fast-aging mice with patches of missing fur began to recover their coats after 10 days. After about three weeks, fitness benefits began to show, with older mice running double the distance of their counterparts who did not receive the peptide. A month after treatment, aged mice showed an increase in markers indicating healthy kidney function.

Senescent cell therapy is one of several strategies being tested in mice aimed at reversing aging or lengthening healthspan. In 2015, the Valter Longo laboratory at the University of Southern California reported that mice on a calorie-restricted diet that mimics fasting benefited from a longer life, a reduction in inflammatory disease, and improved memory (Cell Metabolism, 10.1016/j.cmet.2015.05.012). And last December, Juan Carlos Izpisua Belmonte at the Salk Institute of Biological Science and colleagues made headlines with their discovery that cellular reprogramming of epigenetic marks could extend lifespan and improve health in fast-aging mice (Cell, 10.1016/j.cell.2016.11.052).

"This wave of research on how we can fight aging is complementary, and not in competition," says de Keizer. "The common thread I see for the future of anti-aging research is that there are three fronts in which we can improve: The prevention of cellular damage and senescence, safe therapeutic removal of senescent cells, to stimulate stem cellsno matter the strategyto improve tissue regeneration once senescence is removed."

de Keizer aims to start a company based on these findings, but in the short term, he and his group want to show that their peptide is non-toxic in humans with no unforeseen side effects. They plan to offer a safety clinical trial in people with Glioblastoma multiforme, an aggressive brain tumor, which also shows high levels of the biomarkers needed for this FOXO4 peptide to be effective.

Explore further: Anti-aging therapies targeting senescent cells: Facts and fiction

More information: Cell, Baar et al.: "Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging" http://www.cell.com/cell/fulltext/S0092-8674(17)30246-5 DOI: 10.1016/j.cell.2017.02.031

Sebastian Brandhorst et al. A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration, Enhanced Cognitive Performance, and Healthspan, Cell Metabolism (2015). DOI: 10.1016/j.cmet.2015.05.012

Alejandro Ocampo et al. In Vivo Amelioration of Age-Associated Hallmarks by Partial Reprogramming, Cell (2016). DOI: 10.1016/j.cell.2016.11.052

Journal reference: Cell Cell Metabolism

Provided by: Cell Press

It's an exciting time to be an elderly mouse. Researchers believe that by removing senescent cells (cells with a persistent damage response), which naturally accumulate with age, senior rodents can regrow hair, run faster, ...

Most cells can divide only a limited number of times and eventually undergo permanent cell cycle arrest, a state known as cellular senescence. Cellular senescence is mediated by activation of specific cellular signaling pathways ...

An enzyme that blocks cellular senescence and its mechanisms has been discovered by a research team from Kumamoto University, Japan. They found that a reduction of the enzyme SETD8, which regulates cell proliferation and ...

Mayo Clinic researchers have uncovered three new agents to add to the emerging repertoire of drugs that aim to delay the onset of aging by targeting senescent cells - cells that contribute to frailty and other age-related ...

Researchers at Mayo Clinic have shown that senescent cells - cells that no longer divide and accumulate with age - negatively impact health and shorten lifespan by as much as 35 percent in normal mice. The results, which ...

A Mayo Clinic study has shown evidence linking the biology of aging with idiopathic pulmonary fibrosis, a disease that impairs lung function and causes shortness of breath, fatigue, declining quality of life, and, ultimately, ...

Men unable to have an erection after prostate surgery enjoyed normal intercourse thanks to stem cell therapy, scientists are to report Saturday at a medical conference in London.

McMaster University researchers have discovered that while survivors of childhood brain tumours have a similar Body Mass Index (BMI) to healthy children with no cancer, they have more fat tissue overall, and especially around ...

Wellcome Trust Sanger Institute scientists and their collaborators at the University of Cambridge have created a new technique that simplifies the production of human brain and muscle cells - allowing millions of functional ...

Regular infusions of a peptide that can selectively seek out and destroy broken-down cells that hamper proper tissue renewal, called senescent cells, showed evidence of improving healthspan in naturally-aged mice and mice ...

People with cystic fibrosis (CF) suffer repeated lung infections because their airway mucus is too thick and sticky to keep bacteria, viruses, and other pathogens from causing chronic infection. How mucus becomes abnormal ...

Scientists at The Rockefeller University have mapped the three-dimensional structure for one of the more notorious disease-causing molecules in the human body: the protein responsible for the genetic disorder cystic fibrosis. ...

Adjust slider to filter visible comments by rank

Display comments: newest first

This -- if true -- is one of the most important scientific reports ever!

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

See the article here:
Peptide targeting senescent cells restores stamina, fur, and kidney function in old mice - Medical Xpress

Study shows potential of stem cell therapy to repair lung damage – Hindustan Times

Researchers found that along with reducing inflammation in the lung, Mesenchymal stem cell therapy also resulted in significant improvements in lung structure, suggesting that this form of treatment has the potential to repair the damaged lung.

Stem cell therapy may potentially reduce lung inflammation in patients suffering from chronic obstructive pulmonary disease (COPD) and cystic fibrosis, a new study conducted on mice suggests.

Researchers from Queens University Belfast in the UK investigated the effectiveness of Mesenchymal stem cell (MSC) therapy in a mouse model of chronic inflammatory lung disease, which reflects some of the essential features of diseases such as COPD and cystic fibrosis.

They delivered stem cells intravenously to mice at four and six weeks of age, before collecting sample tissue and cells from the lungs at about eight weeks.

These findings were compared to a control group that did not receive the MSC therapy. The results showed that inflammation was significantly reduced in the group receiving MSC therapy.

Cell count for both monocytic cells and neutrophils - signs of inflammation - were significantly reduced after MSC therapy, researchers said.

Analysis of lung tissue revealed a reduction in the mean linear intercept and other measures of lung destruction in MSC treated mice.

Read more

Researchers found that along with reducing inflammation in the lung, MSC therapy also resulted in significant improvements in lung structure, suggesting that this form of treatment has the potential to repair the damaged lung.

These preliminary findings demonstrate the potential effectiveness of MSC treatment as a means of repairing the damage caused by chronic lung diseases such as COPD, said Declan Doherty of Queens University Belfast.

The ability to counteract inflammation in the lungs by utilising the combined anti-inflammatory and reparative properties of MSCs could potentially reduce the inflammatory response in individuals with chronic lung disease whilst also restoring lung function in these patients, Doherty added.

Lung damage caused by chronic inflammation in conditions such as COPD and cystic fibrosis leads to reduced lung function and eventually respiratory failure.

MSC therapy is currently being investigated as a promising therapeutic approach for a number of incurable, degenerative lung diseases.

Follow @htlifeandstyle for more

More here:
Study shows potential of stem cell therapy to repair lung damage - Hindustan Times

Erectile dysfunction: Stem cell therapy restores sexual function in phase I trial – Medical News Today

Early results of a clinical trial suggest that stem cell therapy may be a promising treatment for erectile dysfunction, after the procedure was found to restore sexual function in men with the condition.

The stem cell therapy involves injecting the patients' own stem cells - derived from abdominal fat cells - into the erectile tissue of the penis.

Lead researcher Dr. Martha Haahr, of Odense University Hospital in Denmark, and colleagues found that within 6 months of the procedure, 8 of the 21 men treated were able to engage in spontaneous sexual intercourse.

The researchers recently presented their findings at EAU17 - the European Association of Urology's annual conference - held in London in the United Kingdom.

Erectile dysfunction (ED) is a condition whereby a man has difficulties getting or maintaining an erection in order to engage in sexual intercourse.

According to the National Institute of Diabetes and Digestive Kidney Diseases, around 12 percent of men under the age of 60, and 22 percent of men aged between 60 and 69, have ED.

High blood pressure, diabetes, heart disease, chronic kidney disease, and prostate surgery are some of the physical conditions that can cause ED. Psychological issues - such as anxiety, stress, depression, and low self-esteem - can also contribute to ED.

Current treatments for ED include PDE5 inhibitors (such as Viagra), penile implants, and injections. However, Dr. Haahr and team note that all of these therapies can have significant side effects.

As a result, researchers are on the hunt for alternative treatments for ED, and stem cell therapy has emerged as a promising candidate in animal trials.

In their phase I trial, Dr. Haahr and colleagues tested stem cell therapy on 21 men who had ED as a result of undergoing radical prostatectomy for prostate cancer. None of the men had responded to standard medical treatment for ED.

For the stem cell procedure, abdominal fat cells were extracted from each man through liposuction. Stem cells were then isolated from the fat cells and injected into the corpus cavernosum of the penis - the spongy tissue that normally becomes filled with blood during an erection.

Before the stem cell procedure and 6 and 12 months after, the participants' erectile function was assessed using the International Index of Erectile Function (IIEF) questionnaire. An IIEF score of 5-7 represents severe erectile dysfunction, 12-16 is mild to moderate erectile dysfunction, and 22-25 is no erectile dysfunction.

All 21 men saw their erectile function improve with stem cell therapy: their IIEF score increased from 6 prior to treatment to 12 at 6 months after treatment.

Eight of the men reported that they had been able to engage in spontaneous sexual activity 6 months after stem cell therapy, and this outcome remained evident at 12 months after treatment. These men saw their IIEF score rise from 7 to 14 with stem cell therapy.

"What we have done establishes that this technique can lead to men recovering a spontaneous erection - in other words, without the use of other medicines, injections, or implants," says Dr. Haahr.

Although the study findings are preliminary, the team says that they show promise for stem cell therapy as an effective treatment strategy for ED.

"We are the first to use a man's own fat stem cells as a treatment for erectile dysfunction in a clinical trial. The technique has been trialed in animal work, but this is the first time stem cell therapy has allowed patients to recover sufficient erectile function to enable intercourse," says Dr. Haahr.

"We are pleased with the preliminary outcomes, especially as these men had previously seen no effect from traditional medical treatment and continue to have good erectile function after 12 months follow-up, indicating that this might be a long-term solution.

This suggests the possibility of therapeutic options for patients suffering from erectile dysfunction from other causes. But we need to remember that this is a small trial, with no control group. We're still some time away from a clinically available solution."

Dr. Martha Haahr

The researchers are now in the process of initiating a phase II trial to further investigate the safety and efficacy of stem cell therapy for ED.

Learn how eating more fruits could help to lower the risk of ED.

Originally posted here:
Erectile dysfunction: Stem cell therapy restores sexual function in phase I trial - Medical News Today